Repository logo
 
Publication

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIENĀ®) and Follow-Up Considerations/Recommendations

2020-07-24Journal article Open access
Simple item page
dc.contributor.authorAdƔn, Alfredo
dc.contributor.authorCabrera, Francisco
dc.contributor.authorFigueroa, Marta S
dc.contributor.authorCervera, Enrique
dc.contributor.authorAscaso, Francisco J
dc.contributor.authorUdaondo, Patricia
dc.contributor.authorAbraldes, Maximino
dc.contributor.authorReyes, Miguel Ɓngel
dc.contributor.authorPazos, Marta
dc.contributor.authorPessoa, Bernardete
dc.contributor.authorArmadĆ”, FĆ©lix
dc.date.accessioned2021-05-20T13:39:34Z
dc.date.available2021-05-20T13:39:34Z
dc.date.issued2020-07-24
dc.description.abstractCurrent management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting between 1 and 6 months) require frequent injections to maintain efficacy, meaning a considerable treatment burden for diabetic patients with multiple comorbidities. Continuous injections needed in some cases are an economic burden for patients/healthcare system, so real-life clinical practice tends to adopt a reactive approach, ie, watch and wait for worsening symptoms, which consequently increases the risk of undertreatment and edema recurrence. On March 7th 2019, a group of experts in retinal medicine and surgery held a roundtable meeting in Madrid, Spain to discuss how to (1) optimize clinical outcomes through earlier use of fluocinolone acetonide (FAc) implant (ILUVIENĀ®) in patients with persistent or recurrent DME despite therapy; and, (2) to provide guidance to assist physicians in deciding which patients should be treated with ILUVIEN. In this regard, a 36-month follow-up consensus protocol is presented. In conclusion, patients that achieve a complete or partial anatomical, and preferably functional, response following one or two intravitreal dexamethasone implants, but with recurrence of edema after 3-4 months, are deemed by the authors most likely to benefit from ILUVIEN, and the switch to FAc implant should not be delayed more than 12 months after the initiation of at least the first dexamethasone implant.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAdĆ”n A, Cabrera F, Figueroa MS, Cervera E, Ascaso FJ, Udaondo P, Abraldes M, Reyes MƁ, Pazos M, Pessoa B, ArmadĆ” F. Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIENĀ®) and Follow-Up Considerations/Recommendations. Clin Ophthalmol. 2020 Jul 24;14:2091-2107. doi: 10.2147/OPTH.S252359. PMID: 32801618; PMCID: PMC7398681.pt_PT
dc.identifier.doi10.2147/OPTH.S252359pt_PT
dc.identifier.issn1177-5483
dc.identifier.urihttp://hdl.handle.net/10400.16/2454
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherDove Medical Presspt_PT
dc.relation.publisherversionhttps://www.dovepress.com/getfile.php?fileID=59995pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectDMEpt_PT
dc.subjectILUVIENpt_PT
dc.subjectdiabetic macular edemapt_PT
dc.subjectfluocinolone acetonide implant therapypt_PT
dc.titleClinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIENĀ®) and Follow-Up Considerations/Recommendationspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceNew Zealandpt_PT
oaire.citation.endPage2107pt_PT
oaire.citation.startPage2091pt_PT
oaire.citation.titleClinical ophthalmology (Auckland, N.Z.)pt_PT
oaire.citation.volume14pt_PT
person.familyNamePessoa
person.givenNameBernardete
person.identifier.ciencia-id0E1B-7EB2-B90F
person.identifier.orcid0000-0002-5673-1561
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationfa0e3b13-5da3-4f74-a184-22358fc19d38
relation.isAuthorOfPublication.latestForDiscoveryfa0e3b13-5da3-4f74-a184-22358fc19d38

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical-Decision Criteria.pdf
Size:
5.16 MB
Format:
Adobe Portable Document Format
Download

Collections

SOFT - Artigos publicados em revistas indexadas na Pubmed/Medline